Variants in ABCB1 can predict patient response to antidepressant drugs
This article has no abstract so we have provided the first paragraph of the full text.
For patients with depression, antidepressant drugs are a principle method of treatment, yet the rate of remission is low. The poor response to antidepressants might to some extent be attributable to inadequate penetration into the CNS, a process that is regulated at the blood–brain barrier in part by the transporter protein P-glycoprotein (P-gp), a known efflux pump for various drugs. To test this hypothesis, Uhr et al. have investigated the relationship between single-nucleotide polymorphisms (SNPs) in the gene that encodes P-gp (ABCB1) and incidence of remission in patients treated with P-gp-substrate antidepressants.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.